Ukoniq (Umbralisib) for Lymphoma | MyLymphomaTeam

Connect with others who understand.

sign up Log in
About MyLymphomaTeam
Powered By

Ukoniq is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with follicular lymphoma who have received at least three previous therapies and adults with marginal zone lymphoma who have received at least one anti-CD20 based therapy. Ukoniq may be also referred to by its drug name, umbralisib.

Ukoniq is a kinase inhibitor. Ukoniq is believed to work by inhibiting cell growth.

How do I take it?
Ukoniq is generally taken orally once daily.

Ukoniq comes in the form of a tablet.

Side effects
The FDA-approved label for Ukoniq lists common side effects including diarrhea, fatigue, nausea, vomiting, musculoskeletal pain, anemia, abdominal pain, decreased appetite, rash, low white blood cells (neutropenia), and low platelets (thrombocytopenia).

Rare but serious side effects listed for Ukoniq include infections, low white blood cells (neutropenia), diarrhea, liver toxicity, and allergic reactions.

For more details about this treatment, visit:

Ukoniq — TG Therapeutics

Ukoniq — RxList

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in